Involvement of ovarian kinin-kallikrein system in the pathophysiology of ovarian hyperstimulation syndrome: studies in a rat model.
The purpose of the present study was to investigate a possible participation of the kinin-kallikrein system (KKS) in the pathophysiology of ovarian hyperstimulation syndrome (OHSS). Symptoms of hyperstimulation were produced in immature female rats using equine chorionic gonadotrophin followed by human chorionic gonadotrophin (HCG). At 48 h after the HCG injection, rats were injected s.c. with 100 microg/kg of HOE140, bradykinin-2 receptor antagonist. Capillary permeability was evaluated using peritoneal Evans blue dye (EB) concentrations 30 min after the i.v. injections. The EB concentrations in the hyperstimulated rats were significantly reduced 4 and 6 h after the HOE140 injection, compared with those injected with the vehicle as a control (4.58+/-0.80 versus 8.22+/-0.87 and 4.32+/-0.74 versus 8.35+/-1.03 microg respectively; P < 0.03), indicating the involvement of kinin in the pathophysiology of OHSS in this model. The administration of 10 IU aprotinin significantly reduced the peritoneal EB concentration when compared with the control (4.13+/-0.53 versus 7.95+/-1.06 microg; P < 0.01), implicating a possible role of kallikrein. Furthermore, pretreatment with RU486 (5 or 10 mg/kg) resulted in a significant reduction of ovarian kinin concentrations 48 h after the HCG injection, compared with the control (1.22+/-0.07 or 1.43+/-0.07 versus 1.94+/-0.10 pg/mg; P < 0.005 and P < 0.05 respectively). Similar results were obtained in the peritoneal EB concentrations. In addition, a significant correlation between the ovarian kinin and peritoneal EB concentrations was observed (P < 0.001, r = 0.539). Thus it was suggested that ovarian KKS plays an intermediary role in the progesterone-induced augmentation of capillary permeability in this experimental model, indicating the involvement of KKS in the pathophysiology of OHSS.
Ujioka
T
T
Department of Obstetrics and Gynecology, Kumamoto University School of Medicine, Japan.
Matsuura
K
K
Tanaka
N
N
Okamura
H
H
D000818:Animals; D001920:Bradykinin / Q000031:analogs & derivatives / Q000494:pharmacology; D065168:Bradykinin Receptor Antagonists; D002199:Capillary Permeability; D006063:Chorionic Gonadotropin / Q000008:administration & dosage; D004195:Disease Models, Animal; D004958:Estradiol / Q000097:blood; D005070:Evans Blue; D005260:Female; D006727:Hormone Antagonists / Q000494:pharmacology; D007610:Kallikreins / Q000502:physiology*; D007705:Kinins / Q000502:physiology*; D015735:Mifepristone / Q000494:pharmacology; D016471:Ovarian Hyperstimulation Syndrome / Q000139:chemically induced / Q000503:physiopathology*; D010053:Ovary / Q000503:physiopathology*; D010537:Peritoneum / Q000378:metabolism; D011374:Progesterone / Q000037:antagonists & inhibitors / Q000097:blood; D011480:Protease Inhibitors / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar
D065168:Bradykinin Receptor Antagonists; D006063:Chorionic Gonadotropin; D006727:Hormone Antagonists; D007705:Kinins; D011480:Protease Inhibitors; D015735:Mifepristone; D005070:Evans Blue; D011374:Progesterone; D004958:Estradiol; C065679:icatibant; D007610:Kallikreins; D001920:Bradykinin